Novacyt

Equities

ALNOV

FR0010397232

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:26 2024-04-25 am EDT			5-day change	1st Jan Change
0.796 ^EUR	-5.24%		+6.13%	+11.64%

Apr. 19	Novacyt: confident ahead of DHSC trial	CF
Apr. 19	Novacyt expects court to dismiss application by UK DHSC	AN

Novacyt : Liquidity Agreement

October 03, 2022 at 06:25 pm EDT

Novacyt Liquidity Agreement

03 Oct 2022 16:36 CEST

Issuer

NOVACYT

novacyt-liquidity-agreement-03-october-2022-english.pdf

Source

NOVACYT

Provider

Euronext

Company Name

NOVACYT

ISIN

FR0010397232

Symbol

ALNOV

Market

Euronext Growth

Attachments

Original Link
Original Document
Permalink

Disclaimer

Novacyt SA published this content on 03 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 October 2022 22:24:39 UTC.

Latest news about Novacyt

Novacyt: confident ahead of DHSC trial	Apr. 19	CF
Novacyt expects court to dismiss application by UK DHSC	Apr. 19	AN
Novacyt expects court to dismiss application by UK DHSC	Apr. 19	AN
AIM WINNERS & LOSERS: Ethernity loss narrows; Fonix staff sell shares	Apr. 19	AN
Yourgene CEO to become head of Novacyt after acquisition	Apr. 11	AN
Novacyt: changes to the Board of Directors	Apr. 11	CF
Novacyt's New CEO to Start May	Apr. 11	MT
Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024	Apr. 11	CI
Novacyt S.A. Announces CEO Changes, Effective on May 1, 2024	Apr. 11	CI
FTSE 100 Closes Up 0.9%, Lifted by BP	Feb. 06	DJ
Novacyt says talks to sell Taiwan laboratory are terminated	Feb. 06	AN
Novacyt: Taiwanese laboratory retained	Feb. 06	CF
Novacyt's Discussions for Taiwanese Unit Sale Fall Through	Feb. 06	MT
Treatt revenue falls; Secure Trust profit picks up	Jan. 25	AN
Novacyt appoints new CFO	Jan. 02	CF
Novacyt promotes Finance Director Steve Gibson to CFO	Jan. 02	AN
Novacyt Names Finance Director as New CFO	Jan. 02	MT
Novacyt notes delay of divestment as awaits approvals	Dec. 21	AN
FTSE 100 Closes Down 0.3% Dragged by Oil Stocks	Dec. 21	DJ
Novacyt: sale to Taiwan not finalized before 2024	Dec. 21	CF
Novacyt Delays Closure of Yourgene Health Taiwan's Sale	Dec. 21	MT
Actual Experience appoints administrators	Nov. 07	AN
Novacyt: IVDR accreditation for Yourgene DPYD test	Nov. 07	CF
Novacyt Receives EU Certification for Cancer Enzyme Deficiency Diagnosis; Shares Soar	Nov. 07	MT
Novacyt S.A. Announces IVDR Certification for DPYD Genotyping Assay	Nov. 07	CI

Chart Novacyt

Duration

Period

More charts

Company Profile

Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors: - development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests; - manufacture and sale of molecular screening kits (Primerdesign): for laboratories.

Sector

Biotechnology & Medical Research

Calendar

2024-09-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Medical Devices

	1st Jan change	Capi.
NOVACYT	+11.64%	63.32M
MIMEDX GROUP, INC.	-28.79%	949M
NIBEC CO., LTD.	-20.09%	131M
COLLPLANT BIOTECHNOLOGIES LTD.	-16.12%	61.96M
KIM FOREST ENTERPRISE CO., LTD.	+7.05%	60.9M
BONUS BIOGROUP LTD.	+0.60%	52.2M

Bio Medical Devices